Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update
March 11, 2021 16:07 ET
|
Spero Therapeutics, Inc.
Tebipenem HBr advancing towards NDA submission in the second half of 2021 Conference call and live webcast at 4:30 p.m. EST today CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Spero...
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021
March 03, 2021 08:30 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present at Investor Conferences in March
February 25, 2021 08:30 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial
February 05, 2021 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 29, 2021 17:17 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr
January 21, 2021 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer
December 17, 2020 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Added to the NASDAQ Biotechnology Index
December 16, 2020 08:30 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease
December 10, 2020 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer
December 02, 2020 08:30 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...